Stockscreener 앱 받기
7.73
12.16%
-1.07
시간 외 거래:
7.73
전일 마감가:
$8.80
열려 있는:
$8.01
하루 거래량:
3.68M
Relative Volume:
2.46
시가총액:
$1.30B
수익:
$61.10M
순이익/손실:
$-138.36M
주가수익비율:
-5.7259
EPS:
-1.35
순현금흐름:
$-90.59M
1주 성능:
-4.92%
1개월 성능:
+21.64%
6개월 성능:
-26.87%
1년 성능:
+25.28%
1일 변동 폭
$7.6201
$8.3339
1주일 범위
$7.6201
$8.895
52주 변동 폭
$4.79
$11.78
Ocular Therapeutix Inc Stock (OCUL) Company Profile
명칭
Ocular Therapeutix Inc
전화
781-357-4000
주소
15 CROSBY DRIVE, BEDFORD, MA
OCUL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
7.73 | 1.30B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-08 | 개시 | William Blair | Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-03-11 | 개시 | Needham | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-20 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-02-09 | 개시 | BofA Securities | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-08-10 | 재개 | Berenberg | Buy |
| 2021-08-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-11-13 | 재확인 | Raymond James | Strong Buy |
| 2020-08-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-03 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-05-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-21 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-11-15 | 개시 | Raymond James | Strong Buy |
| 2018-09-07 | 개시 | Piper Jaffray | Overweight |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2017-07-26 | 개시 | H.C. Wainwright | Buy |
| 2017-07-12 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-06-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-08-11 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | 개시 | Morgan Stanley | Overweight |
모두보기
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
Ocular Therapeutix Advances in Retinal Treatment Trials - TipRanks
Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus
Ocular Therapeutix: Q1 Earnings Snapshot - MySA
Ocular Therapeutix sees cash runway into 2028 - TipRanks
Ocular Therapeutix (OCUL) Stock Drops 13% After Q1 Earnings - Benzinga
Ocular Therapeutix reports Q1 EPS (38c), consensus (28c) - TipRanks
Ocular Therapeutix Inc (OCUL) Q1 2025 Earnings: EPS of $(0.38) M - GuruFocus
Ocular Therapeutix stock tumbles as Q1 results miss estimates By Investing.com - Investing.com Canada
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates - Nasdaq
Ocular Therapeutix Inc reports results for the quarter ended March 31Earnings Summary - TradingView
OCULAR THERAPEUTIX, INC SEC 10-Q Report - TradingView
Ocular Therapeutix Inc earnings missed by $0.09, revenue fell short of estimates - Investing.com
OCUL's Financial Position: Cash Reserves Expected to Sustain Until 2028 | OCUL Stock News - GuruFocus
Ocular Therapeutix Inc (OCUL) Q1 2025 Earnings: EPS of $(0.38) Misses Estimate, Revenue Falls Short at $10.7 Million - GuruFocus
Ocular Therapeutix (OCUL) Advances Retinal Therapy Pipeline Amid Revenue Miss | OCUL Stock News - GuruFocus
Ocular Therapeutix Q1 Net Loss Narrows, Revenue Falls - marketscreener.com
Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights | OCUL Stock News - GuruFocus
Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights - The Manila Times
Ocular Therapeutix Reports First Quarter 2025 Results and Business Highlights - TradingView
BRIEF-Ocular Therapeutix Q1 EPS USD -0.38 Vs. IBES Estimate USD -0.29 - TradingView
Ocular Therapeutix Earnings: $349M War Chest Powers AXPAXLI Trials as FDA Backs NPDR Program - Stock Titan
Ocular Therapeutix Inc (OCUL) Q1 2025: Everything You Need To Kn - GuruFocus
Neuropathic Ocular Pain Pipeline 2025: In-depth Clinical - openPR.com
Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences - GlobeNewswire
Ocular Therapeutix to Present Groundbreaking Retina Treatment Results Across 5 Major Healthcare Events - Stock Titan
Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025 - GlobeNewswire
JPMorgan Chase & Co. Has $1.62 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Ocular Therapeutix Inc’s Market Journey: Closing Strong at 7.91, Up 3.94 - DWinneX
How To Trade (OCUL) - news.stocktradersdaily.com
Hydrogel-Based Drug Delivery System Market Detailed In New - openPR.com
Investors bid Ocular Therapeutix (NASDAQ:OCUL) up US$202m despite increasing losses YoY, taking three-year CAGR to 24% - simplywall.st
Primary Open Angle Glaucoma Therapeutics Market Size in 7MM - openPR.com
Ocular Therapeutix (NASDAQ:OCUL) Now Covered by William Blair - MarketBeat
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listin - GuruFocus
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Strategic Hire: Ocular Therapeutix Strengthens Leadership with Key Payer Access Executive - Stock Titan
Key Trends Shaping the Future of Ocular Implants Market:Ocular Therapeutix Launches Clinical Trial For Axit... - WhaTech
William Blair Initiates Coverage of Ocular Therapeutix (OCUL) with Outperform Recommendation - MSN
DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
Ocular Hypertension Pipeline Analysis and Clinical Trials - openPR.com
Expert Outlook: Ocular Therapeutix Through The Eyes Of 5 Analysts - Benzinga
William Blair starts Ocular Therapeutix stock with Outperform By Investing.com - Investing.com Canada
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
William Blair Initiates Ocular Therapeutix With Outperform Rating - marketscreener.com
Buy Recommendation for Ocular Therapeutix: Axpaxli’s Potential to Revolutionize nAMD Treatment - TipRanks
Ocular Therapeutix at Needham Conference: Strategic Moves in Eye Care By Investing.com - Investing.com Canada
Ocular Therapeutix at Needham Conference: Strategic Moves in Eye Care - Investing.com India
How to Take Advantage of moves in (OCUL) - news.stocktradersdaily.com
Top Premarket Decliners - MarketScreener
Ocular Therapeutix Inc (OCUL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):